Tiziana’s Phase IIa trial of foralumab meets dual endpoints in na-SPMS
Tiziana Life Sciences has reported that its Phase IIa INFORM-MS study of intranasal foralumab for na-SPMS met its dual primary endpoints.
The post Tiziana’s Phase IIa trial of foralumab meets dual endpoints in na-SPMS appeared first on Clinical Trials Arena .